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Abstract
Type 1 diabetes is associated with high morbidity and mortality from microvascular and 
macrovascular disease with considerable economic cost to society. Islet cell transplanta-
tion (ICT) is a treatment option recommended by National Institute for Health and Care 
Excellence (NICE) for people with debilitating hypoglycaemia due to type 1 diabetes, 
including those with renal failure where kidney transplantation may also be indicated. 
The primary aim of ICT is to improve glycaemic control, reduce severe hypoglycae-
mia, stabilise glycaemic variability and restore awareness of hypoglycaemia where this 
is compromised. Insulin independence, although not a primary aim, should also be con-
sidered a therapeutic goal. The impact ICT has on the progression of microvascular and 
macrovascular diabetes complications is derived from small studies and has not been 
examined in large clinical trials. Lifelong immunosuppression, which is necessary to 
avoid transplant rejection, has adverse effects on lipid metabolism, hypertension and 
renal function, which must also be considered. In this review, we discuss the role of ICT 
in type 1 diabetes management and the available evidence with respect to microvascular 
and macrovascular disease progression post- transplantation. We conclude that, following 
ICT, microvascular complications including retinopathy and neuropathy are stabilised or 
improved. Effects on nephropathy can be complicated by coexisting kidney transplanta-
tion and the impact of immunosuppression, the latter leading to an early decline in renal 
function; however, there is evidence to suggest stable renal outcomes in the long term. 
Short- term studies have demonstrated a positive impact of ICT on surrogate markers of 
macrovascular disease; however, long- term studies and trials in this area are lacking.
K E Y W O R D S
islet transplantation, macrovascular disease, microvascular disease, type 1 diabetes
What's new?
• Islet transplantation is a treatment option recommended by NICE for recurrent se-
vere hypoglycaemia with impaired awareness of hypoglycaemia in Type 1 diabetes 
where conventional insulin therapy has been optimised.
• Microvascular complications including retinopathy, sensory neuropathy and long- 
term renal function (eGFR) are stabilised or improved following islet transplantation.
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial License, which permits use, distribution and reproduction in any medium, 
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• Benefits of islet transplantation on nephropathy and macrovascular complications 
may be hindered by the negative impact of immunosuppression; randomised con-
trolled trials examining long term cardiovascular outcomes are awaited.
1 |  INTRODUCTION
Diabetes affects an estimated 422 million adults worldwide1 
with high morbidity and mortality from microvascular and 
macrovascular complications. Microvascular complications 
include retinopathy, nephropathy and neuropathy. Diabetic 
retinopathy is the most common cause of blindness in people 
with type 1 diabetes (T1D); it has been estimated that a third 
of people with diabetes have signs of diabetic retinopathy and 
that 10% of those have signs of sight- threatening retinopathy, 
one of the leading causes of blindness in working- age peo-
ple.2 Up to 40% of people with T1D will develop diabetic ne-
phropathy in their life time, of which 75% develop end stage 
renal disease within 10 years.3 Macrovascular complications 
include myocardial ischaemia, myocardial infarction and 
stroke.4 Data from the Diabetes Control and Complications 
Trial (DCCT) cohort has shown that those with T1D have a 
cumulative incidence of cardiovascular disease of 14% after 
30 years of diabetes.5
Management of T1D focusses on structured education 
programmes with intensive insulin therapy via multiple daily 
injections or continuous subcutaneous infusion to achieve 
tight glycaemic control. The DCCT trial demonstrated that 
tight glycaemic control is beneficial in reducing long- term 
microvascular and macrovascular complications of diabe-
tes.6 At 10- year follow- up, the risk of progression of diabetic 
retinopathy was reduced by 53%.7 Similar benefits were 
seen in relation to nephropathy outcomes with a reduction 
in the incidence of microalbuminuria and macroalbumin-
uria, 59% and 84%, respectively, and a 50% risk reduction 
on the development of impaired glomerular filtration rate 
(GFR).3 Follow- up at 30 years demonstrated a reduction in 
the incidence of any cardiovascular event and in major car-
diovascular events, 30% and 32%, respectively, in the former 
intensive treatment group.4 However, for many, insulin doses 
are difficult to titrate, resulting in recurrent hypoglycaemia, 
impaired awareness of hypoglycaemia (IAH) which affects 
around 30% of people, impacting on their quality of life,8 
and putting them at higher risk of seizures or coma with 
major economic impact.9 Islet cell transplantation (ICT) 
is a minimally invasive procedure that may be indicated in 
those with recurrent severe hypoglycaemia (SH) defined by 
the American Diabetes Association as severe cognitive im-
pairment requiring external assistance for recovery,10 where 
treatment has been optimised. It can restore β- cell function, 
reduce hypoglycaemia and glycaemic lability, improve qual-
ity of life and can result in insulin independence.11 Projected 
benefits of improved glycaemic control must be balanced 
against the risks of long- term immunosuppression, includ-
ing the risk of infection and the increased risk of cancer. 
Immunosuppressive drugs also have adverse effects on me-
tabolism and blood pressure with cardiovascular disease 
continuing to be the leading cause of death following whole 
organ transplantation.12
In this review, we will discuss indications for ICT, the 
procedure and immunosuppression used, metabolic and qual-
ity of life outcomes and the evidence to date of the impact 
that ICT has on microvascular and macrovascular disease 
in the early post- transplant period, which we have consid-
ered up to 2  years post- transplant, the intermediate period 
between 2 and 5 years post- transplant, and, in the long term, 
over 5 years post- transplant.
1.1 | Indications for islet cell transplant
The burden of SH on diabetes- related morbidity and mortal-
ity is well established.13 Since the DCCT trials, there have 
been advances with newer short acting insulins and technolo-
gies, including sensor technology and automated insulin de-
livery (AID) devices. These demonstrate that improvements 
in HbA1c may be possible with no increase in hypoglycae-
mia, an outcome that was not apparent at the time of the 
DCCT.6 However, these devices may not be suitable or read-
ily available for all people, and in those with IAH, avoidance 
of hypoglycaemia may not be achievable and awareness of 
hypoglycaemia may not be restored.14
There are a number of islet transplantation programmes 
worldwide. Data from over 1000 people receiving islet trans-
plants since 1999 has been collated via the Collaborative Islet 
Transplant Registry (CITR) which has served to inform best 
practise, including indications for ICT. The United Kingdom 
has a collaborative network of seven centres which together 
form the UK Islet Transplant Consortium (UKITC). The 
United Kingdom introduced this intervention free at the 
point of entry into its health care system; it is endorsed by 
National Institute for Health and Care Excellence (NICE), 
and we have shown that this intervention reaches all socio- 
economic groups in the population.8 It is a therapy for those 
with recurrent neuroglycopaenia, including severe glycaemic 
lability with IAH where insulin therapy has been intensified 
as much as possible. The main aim of ICT is not insulin in-
dependence, but to restore hypoglycaemia awareness, reduce 
glycaemic lability and improve quality of life.
The current criteria for ICT in the United Kingdom are 
summarised in Table 1 and the contraindications in Table 2. 
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Of note, in the United Kingdom, absolute insulin requirements 
rather than insulin doses expressed per kilogram body weight 
are taken into consideration. In people with significantly di-
minished GFRs <20 ml/min, a simultaneous pancreas– kidney 
transplantation would initially be considered in those with T1D 
with problematic glycaemic control. However, this is associ-
ated with a relatively high perioperative risk, and it necessitates 
people to have adequate cardiovascular fitness. If the person 
has multiple co- morbidities and fails cardiopulmonary func-
tion tests, usually carried out before the listing procedure, then 
simultaneous islet and kidney (SIK) transplant where the islet 
cells and kidney come from the same donor, or islet after kidney 
(IAK) transplant, where a new donor is used following a previ-
ous renal transplant, would be indicated.15
1.2 | Islet isolation and 
transplantation procedure
Islets are isolated by infusing the donor pancreas with 
collagenase- based enzymes; the resultant is purified using 
density- graded centrifugation and then assessed before being 
placed in a conventional tissue culture for 24 h before being 
reassessed for purity, viability, sterility and yield.1 If release 
criteria are met, they are infused into the sedated person via 
the hepatic portal vein under radiological guidance. The re-
lease criteria include (1) cell count >250,000 islet equivalents 
(IEQs) (approximately >5000 IEQ/kg), (2) purity >50%, (3) 
viability >70%, (4) sterility defined by a negative gram stain 
and (5) endotoxin content <5 EU/kg.
Recipient blood glucose levels are closely monitored 
perioperatively and kept between 4 and 8 mmol/L using intra-
venous insulin infusions to reduce oxidative stress on the newly 
transplanted islets.16 The number of islets recovered from an 
individual pancreas can vary. Transplanting >10,000 total IEQ 
units per recipient body weight (IEQ/kg) typically from two 
donor pancreases is associated with insulin independence.17 
Occurrence of periprocedural complications is low, with 
infusion- related adverse events occurring in 4.2% of islet trans-
plants from 2015 to 2018 in the first 30 days post- transplant.18
1.3 | Immunosuppression
A major consideration in assessing people for islet transplan-
tation is the use of induction agents and steroid- free immu-
nosuppression which diminishes the risk of alloimmune and 
autoimmune rejection of islets. A previous history of cancer, 
excluding completely excised nonmelanoma skin cancer, is a 
contraindication for receiving immunosuppression and islet 
transplantation. The range of immunosuppression medications 
used in ICT is extensive and has been recently reviewed.19 A 
full discussion of all agents involved is out with the scope of 
this review; however, immunosuppressive agents at the time 
of ICT can impact the risk of microvascular and macrovascular 
complications, and this must be carefully considered.
The most common agents used at induction are alemtu-
zumab: a monoclonal antibody that binds to CD52 present 
on mature lymphocytes, in combination with etanercept: an 
anti- TNF- α agent. Other induction agents include antithymo-
cyte globulin which is composed of rabbit- derived antibodies 
against human T cells and basiliximab: a monoclonal anti-
body to the α chain (CD25) of the IL- 2 receptor of T cells. 
Maintenance immunosuppression in many programmes is 
with tacrolimus, a calcineurin inhibitor (CNI) in combina-
tion with mycophenolate mofetil (MMF), an inhibitor of cell 
division. Other immunosuppression regimens are used and 
include sirolimus, which inhibits IL2 via mTOR (Table 3). 
These are given in the absence of steroids in those receiving 
an islet cell transplant alone.20
Although immunosuppression increases the risk of in-
fection and malignancy, rates of these complications are 
relatively low. Information from the CITR showed an over-
all incidence of malignancy of 0.01 events/person year fol-
low- up. Life threatening events, mainly related to infection 





• C- peptide negative (<0.3 ng/ml)
Severe recurrent problematic hypoglycaemic:
• Impaired awareness of hypoglycaemia
• ≥2 episodes of severe hypoglycaemia in past 2 years
Failure to achieve glycaemic targets despite intensive management 
and structured education:
• Previous trial of CSII and/or CGM or sensor augmented pump 
therapy preferable
T A B L E  2  Contraindications to islet cell transplantation
Contraindications
Due to immunosuppression risks:
• A previous history of cancer, excluding completely excised 
nonmelanoma skin cancer
• Active sepsis
• Active peptic ulceration
Due to lower likelihood of successful transplant outcome:
• High insulin requirements (>100 units/day)
• Weight >85 kg
• Major psychiatric history likely to result in nonconcordance
• Inability to withstand immunosuppression
Due to risks from diabetes complications:
• Active proliferative retinopathy
• Nuclear medicine GFR <60 ml/min/1.73 m2
• Excessive cardiovascular risk
4 of 15 |   REID Et al.
and depleted granulocyte numbers, occurred in 5.4% of re-
cipients between 2007 and 2018. Immunosuppression was 
thought to be linked with six of a total of 33 deaths reported 
post- ICT since the registry began in 2001.18
Immunosuppression may have an impact on microvascu-
lar and macrovascular diabetes complications. Tacrolimus is 
associated with hyperglycaemia, a result of inhibition of in-
sulin secretion and increased insulin resistance which could 
precipitate poor glycaemic control and exacerbate diabetic 
complications. Tacrolimus in the therapeutic range may also 
be associated with peripheral nerve dysfunction and neurop-
athy.21 Of note, however, tacrolimus is anti- inflammatory 
and prevents early retinal neovascularisation in experimental 
models of diabetes.22 Many immunosuppressive agents also 
have adverse effects on renal function,23 at least initially, and 
data from Edmonton have demonstrated that there is an initial 
fall in eGFR over the first year which subsequently stabilises 
and has been noted to remain stable over a 10- year period 
of follow- up.24 Immunosuppression is also associated with 
higher rates of cardiovascular disease which could be related 
to known adverse effects on blood pressure and lipids.23
1.4 | Graft assessments and outcomes
Studies have used a number of measures to reflect graft suc-
cess. These in part reflect the change in the goals of islet 
transplantation that have evolved over time. Improvement in 
HbA1c, insulin independence, C- peptide secretion, reduction 
in insulin doses, reduction of hypoglycaemia, return of hypo-
glycaemia awareness and composite scoring systems which 
incorporate a number of these variables have all been used.
Many of the glycaemic targets used in diabetes stem from 
the DCCT, where intensively controlled participants had 
significantly reduced microvascular risk achieving a me-
dian HbA1c of 53 mmol/mol (7%), compared with a median 
HbA1c of 75 mmol/mol (9%) in those on conventional treat-
ment.6 Evidence from the CITR shows >60% of islet trans-
plant recipients achieve and maintain HbA1c <53  mmol/
mol (<7%) for up to 3 years post- transplant compared with 
fewer than 20% achieving this pre- transplant.18 Other stud-
ies confirm improvements in HbA1c post- transplant.8,25– 27 
Improvements in HbA1c are achieved post- transplant even 
in those with relatively low baseline HbA1c; a 2016 phase 
3 multi- centre trial of 48 people reported a median HbA1c 
of 37 mmol/mol (5.6%), which was attained in the absence 
of SH 2 years post- transplant, from a baseline of 55 mmol/
mol (7.2%).28
Insulin independence post- transplant is defined as a min-
imum period of 14 days without the need for exogenous in-
sulin, coupled with good glycaemic control. Several studies 
have shown insulin independence is achieved for at least 
a short period in nearly all transplanted people, but islet 
transplantation still falls short of a cure.29,30 Continued in-
sulin independence at 1, 2 and 3 years post- islet transplant 
has improved over time with insulin independence rates of 
66%, 55% and 44% in 2007– 2010 compared with 51%, 36% 
and 27% in 1999– 2002.25 Although insulin independence is 
a commonly reported measure of graft success, and a bene-
ficial outcome for ICT recipients, it is not a primary aim of 
islet transplantation.
Measurement of C- peptide positivity is objective and re-
ported in the CITR. Stimulated C- peptide at 90  min using 
a standard mixed meal test (360- ml Ensure HP comprising 
391 kcal with 8.5 g fat, 44 g carbohydrate, 17 g protein) is 
used and interpreted in the context of a paired blood glucose 
reading.31 Reductions in SH and a return in the awareness of 
hypoglycaemia post- transplantation are important outcome 
measures post- islet transplantation,25,26,28,29,32 but the latter is 
not well recorded. Reduction in hypoglycaemia is associated 
with C- peptide positivity,25 independent of the restoration of 
autonomic function,33 and allows people to regain adrenergic 
T A B L E  3  Induction and immunosuppressive agents in islet transplantation
Immunosuppressive agent Mechanism of action Use
Daclizumab IL- 2 inhibitor Early induction agent
Alemtuzumab Monoclonal antibody to CD52 Main induction agent in current use for first islet 
transplant
Basiliximab Monoclonal antibody acting as an IL- 2 receptor 
antagonist
Potential induction agent for islet transplant
Etanercept Anti- TNF- α inhibitor Used in combination with Alemtuzumab or 
antithymocyte globulin for first transplant induction
Antithymocyte globulin Anti- T- cell antibodies Induction agent used in combination with etanercept
Tacrolimus Reduces IL2 up- regulation via calcineurin inhibition Main agent for maintenance immunosuppression
Sirolimus Inhibits IL2 via mTOR inhibition Alternative to mycophenolate mofetil and to 
tacrolimus in patients with declining renal function
Mycophenolate mofetil Inhibits inosine monophosphate dehydrogenase Main adjunct to tacrolimus for maintenance 
immunosuppression
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symptoms.34 Pathophysiologically, glucagon secretion in 
response to hypoglycaemia is partially restored following 
islet transplant35 which is thought to be due to paracrine 
interactions in the transplanted islets between glucagon se-
creting alpha cells and insulin secreting β- cells. The benefit 
is sustained, with more than 90% of islet transplant recipi-
ents remaining free of SH over 5 years of follow- up,25,26,36 
maintained with reintroduction of insulin.26,29 Awareness of 
hypoglycaemia may importantly be retained even with loss 
of graft function.34 Notably, the Trial Comparing Metabolic 
Efficiency of Islet Graft to Intensive Insulin Therapy 
(TRIMECO) was the first randomised controlled trial to 
compare metabolic outcomes in people with T1D following 
ICT (n  =  25) versus those managed with intensive insulin 
therapy (n = 22). After 6 months, participants randomised to 
receive ICT had superior outcomes including significant re-
ductions in SH and HbA1c, with insulin independence rates 
of 11/25 (44%) in the ICT group.37
It is now widely recognised that composite scoring sys-
tems incorporating these variables are powerful measures 
to assess graft function. The beta score (Table S1)38 is com-
monly used. This gives a categorical score ranging from 0 to 
8 based on fasting plasma glucose, HbA1c, daily insulin dose 
or oral hypoglycaemic use and stimulated C- peptide.38 In the 
TRIMECO study, the primary end point was a modified beta 
score ≥6, achieved by 64% of ICT versus 0% of intensively 
insulin- treated group.37 With the advent of highly sensitive 
C- peptide assays, the BETA- 2 score has largely superseded 
the beta score.39 It is a continuous score (Table S2) contain-
ing the same variables as the beta score but uses a fasting 
rather than a stimulated C- peptide, eliminating the need for a 
mixed meal with the benefit of increased frequency of testing 
graft function and cost savings. A BETA- 2 score ≥17 at Day 
75 post- first transplant discriminates people that will not re-
quire exogenous insulin in the longer term.40
A 2018 joint consensus report from the International and 
European Pancreas and Islet Transplantation Associations 
(IPITA/EPITA) recommends the use of clinical and meta-
bolic factors to define islet transplant success, and the current 
British Transplant Society specifically highlights the use of 
the beta and BETA- 2 scores.41 IPITA/EPITA also highlights 
the utility of an HbA1c < 53 mmol/mol (<7%) without SH, 
with >50% reduction in insulin requirement and restoration 
of clinically significant C- peptide secretion.41
Glycaemic variability as assessed by continuous glucose 
monitoring (CGM) has been studied post- ICT, but the liter-
ature is limited. There are reductions in mean glucose, time 
spent in hyperglycaemia and hypoglycaemia and coefficient 
of variation (CV) of glucose.36,42,43 Higher levels of C- peptide 
are required to reduce time in hyperglycaemia versus time in 
hypoglycaemia.44 Our own work has related BETA- 2 scores 
to CGM indices; at 1 year post- transplant, 39 ICT recipients 
had lower time in hypoglycaemia and decreased CV glucose 
versus those on open loop continuous subcutaneous insulin 
infusion (CSII) therapy.43 Over time post- transplant, glycae-
mic variability increases as graft function falls. An area of in-
tensive research currently is how glycaemic variability per se 
contributes to microvascular and macrovascular complications 
as well as quality of life measures independently from HbA1c.
Factors associated with a favourable metabolic outcome 
include induction immunosuppression with T- cell depletion 
and/or a TNF- α inhibitor, maintenance immunosuppression 
with an mTOR inhibitor and CNI, recipient age >35 years 
(associated with reduced autoimmunity) and a transplanted 
mass >325,000 IEQs.18
1.5 | Quality of life
Quality of life (QoL) is an important outcome measure. 
Studies have shown that the psychosocial burden of T1D 
pre- transplant is significant.8,45 The score most frequently 
used to measure QoL is the EQ- 5D- 3L which is not specific 
or sensitive with respect to diabetes. Post- transplant studies 
show improvements in QoL scores following ICT compared 
with pre- transplant.37,46,47 The TRIMECO study showed sig-
nificant improvement in questionnaire scores, the Diabetes 
Quality of Life questionnaire and Short Form36 Health Survey 
(SF- 36), at 6 months in those randomised to receive immedi-
ate transplantation compared with those randomised to con-
tinue with medical therapy.37 Similarly, a recent single- arm 
phase 3 study of IAK recipients found significantly reduced 
diabetes distress and fear of hypoglycaemia scores up to 
3 years post- transplant compared with pre- transplant scores.48 
Improvement is particularly seen for diabetes specific QoL as-
sessments and those relating to hypoglycaemia fears, anxiety 
scores and depression scores in islet transplant alone (ITA). 
While improvements in QoL scores were clear for those re-
ceiving ITA, there were no significant differences in QoL 
scores in SIK/IAK recipients. QoL scores were higher (better 
perceived QoL) at baseline in SIK/IAK groups, which may 
be related to the fact that they did not have a history of SH.47
There is a need to use sensitive QoL assessments, and we 
propose that as this outcome measure is so important, weight 
is given both to this assessment and the metabolic assessment 
including glycaemic variability.
2 |  MICROVASCULAR AND 
MACROVASCULAR DIABETES 
COMPLICATIONS
There is evidence that ICT has a positive impact on the mi-
crovascular complications associated with T1D, such as 
retinopathy, sensory neuropathy and nephropathy. There is 
less evidence with respect to macrovascular complications. 
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All such studies have to be interpreted in the context that ICT 
recipients are on immunosuppression.
3 |  Microvascular complications
3.1 | Retinopathy
A meta- analysis suggests that ICT may be more effective 
than medical therapy in preventing diabetic retinopathy for 
people with longer durations of diabetes, although only three 
islet studies were included.49 A retrospective analysis of reti-
nal screening records from >100 islet transplant recipients, 
including our own islet transplant cohort, found retinopathy 
progression was significantly reduced following islet trans-
plantation compared with a cohort managed with intensive 
multiple daily injections of insulin.50 In a prospective crosso-
ver study, rates of retinopathy progression in people awaiting 
islet transplantation were compared with progression rates 
following islet transplant (S1). From a total of 44 participants 
who were receiving intensive medical therapy on the islet 
transplant waiting list, 27 people received an islet transplant 
and crossed over to form the treatment group. Progression 
rates in both eyes pre- transplant for those in the intensive 
medical group who had not yet received a transplant (n = 17) 
and who had been on the waiting list during the study but 
were later transplanted (n = 27) were compared with retin-
opathy progression post- transplant (n = 27). Mean follow- up 
time was 36 months in the islet group and 34 months in the 
intensive medical group. Eyes were excluded if they had vit-
rectomy prestudy or were blind (six eyes). When compared 
with retinopathy progression in the islet group (0/51 eyes), 
retinopathy progression was significantly more likely in the 
intensively treated medical groups (progression in 10/82 eyes 
in all waiting list participants, p < 0.01 and 6/51 eyes in par-
ticipants who were later transplanted, p < 0.02). Participants 
in the medical group with more advanced retinopathy at 
baseline were more likely to progress. At subsequent follow-
 up, 66 months in islet group, 47 months in medical group no 
additional patients had developed retinopathy progression.30
Islet cell transplantation significantly improves HbA1c,44 
and the adverse effects of abrupt tightening of glucose con-
trol on retinopathy progression remain a concern (S2, S3). 
An early report from the Edmonton group showed 4/47 par-
ticipants receiving islet transplants had a deterioration in reti-
nopathy requiring photocoagulation or vitrectomy within the 
first 5 months of transplant29; however, this was a high- risk 
group with proliferative retinopathy present in 46% of people 
at baseline. Other small studies have shown stable disease in 
the early post- transplant period (S4, S5). Such studies also 
concord with whole organ pancreas transplantation studies 
which demonstrate stabilisation of diabetic retinopathy over 
6– 60 months of follow- up (S6).
Reduced retinal blood flow may be an early sign of ret-
inopathy. Blood flow velocities to the central retinal artery 
and vein on colour Doppler were increased in 10 ICT recip-
ients 1 year after transplant versus matched controls on the 
islet transplant waiting list (S7). This may be consistent with 
reduced progression of diabetic retinopathy, but the exact 
clinical impact of this finding remains uncertain.
Overall, the literature suggests ICT improves or stabilises 
diabetic retinopathy at a cellular and clinical level. It is not 
known if glycaemic variability predicts retinopathy progres-
sion independently from HbA1c (S8). Careful prospective 
studies examining the independent effect of glycaemic vari-
ability and HbA1c as well as their potential additive effects 
on retinopathy outcomes are required. Studies examining the 
effects of islet transplantation on diabetic retinopathy are 
summarised in Table 4.
3.2 | Neuropathy
Studies of the effects of ICT on neuropathy have emerged 
over the past few years. A crossover study compared the 
rate of change of nerve conduction velocities (NCVs) over 
6 years post- transplant with changes in participants await-
ing transplantation on intensive medical therapy. NCV 
scores were measured from seven nerves in each participant 
and a standardised score (‘Z score’) was calculated to allow 
the total burden of neuropathy from multiple nerves to be 
assessed. Diabetic neuropathy was present at baseline in 
29/44 (66%) of all study participants though the proportion 
with baseline neuropathy who were transplanted and crossed 
over to the ICT group were not specified, and there was 
significant heterogeneity in the baseline ‘Z scores’ across 
participants. ICT recipients trended towards improved NCV 
scores versus medically treated controls (p  =  0.11), with 
significant improvements when participants with baseline 
neuropathy were evaluated (p  <  0.05) (S9). This is simi-
lar to previous studies showing improvements post- ICT 
in sensory NCV over 5 years in both IAK and ITA recipi-
ents, compared with their pre- transplant baselines. Motor 
NCV showed no improvement, and a deleterious effect 
of tacrolimus on motor neuropathy was postulated (S10). 
To minimise confounding effects of immunosuppression 
on neuropathy, a study compared T1D transplant recipi-
ents receiving IAK with those receiving kidney transplant 
alone (KTA). They demonstrated significant improvement 
in NCV Z scores in IAK versus KTA controls at 4 years, 
although significance was lost at 6  year follow- up when 
9/18 IAK participants were assessed (mean IAK follow- up 
53.4 months post- transplant). This study showed reductions 
in advanced glycation products and their receptors in skin 
biopsies of islet recipients, which are thought to be asso-
ciated with the pathogenesis of diabetic neuropathy (S11). 
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Other centres have demonstrated stable neuropathy post- 
islet transplantation, although control groups were lacking 
(29, S4, S5).
ICT appears to stabilise or improve sensory neuropa-
thy but not motor neuropathy post- transplant. Longer term 
follow- up may elucidate the impact on motor neuropathy. 
Studies examining the effects of islet transplantation on neu-
ropathy are summarised in Table 5.
3.3 | Nephropathy
Assessment of nephropathy post- ICT is complicated by the 
effects of pre- transplant variability in renal function and 
the use of different combinations of potentially nephrotoxic 
medications, particularly immunosuppression. Whether par-
ticipants are receiving an ITA, SIK or IAK also needs to be 
considered as the latter two groups may have complications 
secondary to pre- transplant renal failure and uraemia, and 
poorer baseline renal function is associated with higher rates 
of albuminuria post- transplant (S12).
Studies of ITA recipients show decline in renal func-
tion post- transplant compared with baseline pre- transplant 
levels.28,29 This concords with results from CITR assessing 
677 individuals with both uraemic and nonuraemic baselines 
showing eGFR declines with time.25 The Edmonton retro-
spective analysis of islet transplant recipients up to 10 years 
post- transplant, the majority of whom were on immunosup-
pression with tacrolimus and MMF, showed progression 
of albuminuria and decline in eGFR of up to 30% at 5 year 
follow- up which then stabilised.24 Conversely, a study com-
paring renal function in 16 recipients pre- and post- ITA30 
demonstrated that the median rate of eGFR decline was 
significantly reduced from −6.7  ml/min/1.73  m2/year pre- 
transplant to −1.3 ml/min/1.73 m2/year post- transplant and 
was not affected by the degree of baseline proteinuria. This 
study used antithymocyte globulin and basiliximab as induc-
tion agents and a combination of tacrolimus and MMF for 
maintenance immunosuppression.
These studies made comparisons to renal function pre- 
transplant and lacked a separate nontransplanted control 
group. Some decline in renal function is expected with 
time in people with T1D and should be considered when 
interpreting change in renal function in these studies. In 
the DCCT, those with normoalbuminuria showed a mean 
rate of change in eGFR of 1.2% per year, while those with 
microalbuminuria, or those who developed macroalbumin-
uria, had a mean rate of change of 1.8% and 5.7% per year 
respectively.3
While studies have not confirmed benefits of ICT in pre-
venting diabetic nephropathy in native kidneys, evidence 
suggests that it may be protective for transplanted kidney 
grafts. (S13, S14). A recent prospective study in 24 IAK 
recipients showed relatively stable renal function over 3 years 
post- transplant, with eGFR of 78  ml/min/1.73  m2 from a 
baseline of 82  ml/min/1.73  m2.48 IAK recipients (n  =  24) 
with C- peptide present versus those with unsuccessful grafts 
(n  =  12 IAK) with C- peptide absent had better renal graft 
survival rates of 83% versus 51% in the respective groups 
at 7 years follow- up (S13). Glycaemic control (HbA1c) be-
tween the groups was not significantly different, but the C- 
peptide positive group had increased Na/K ATPase activity 
and a reduction in natriuresis over time. It is not known if C- 
peptide contributed to kidney graft function, acting via Na/K 
ATP channels to improve sodium resorption in renal tubular 
cells (S13). It is also not clear whether IAK recipients with 
unsuccessful islet grafts may be more immunologically sus-
ceptible to rejecting their kidney graft, which makes the data 
difficult to interpret.
Evaluation of IAK renal outcomes relative to other renal 
transplant recipients has also proved useful in evaluating 
the specific benefits from islet transplantation itself. IAK 
recipients with successful islet grafts previously described 
(n  =  24 people) were compared with those with T1D re-
ceiving either simultaneous pancreas and kidney transplant 
(SPK; n = 166 people) or KTA (n = 44 people) (S14). KTA 
recipients showed a significant increase in urinary albumin 
excretion and creatinine levels over 6 years, while successful 
IAK and SPK recipients showed no significant decline (S14). 
This is concordant with another study showing comparable 
outcomes in IAK and SPK recipients, with no significant dif-
ferences observed in the rate of decline in eGFR over a ten 
year follow- up period.32
Changes to renal function in ICT involving both native 
and transplanted kidneys will also be impacted by the im-
munosuppression used. CNIs such as tacrolimus are neph-
rotoxic and changes in immunosuppression from tacrolimus 
to MMF in people with declining eGFR post- transplant 
has been shown to stabilise renal function (S12, S15). It 
is common clinical practise to switch from tacrolimus to 
the mTOR inhibitor sirolimus when GFRs diminish post- 
transplantation, and there is evidence that this is protective 
in the short term (S16). Sirolimus is also associated with 
post- transplant microalbuminuria (S12) and proteinuria; in 
some reports, proteinuria resolves following withdrawal of 
sirolimus (S17).
Most studies in IAK recipients show a decline in renal 
function post- transplantation in the initial phase secondary 
to immunosuppression— mainly tacrolimus. Graft function 
then stabilises over time, but there is still a valid concern 
that immunosuppression with tacrolimus increases the risk 
of worsening renal function, in which case alternative immu-
nosuppression may be used. The field is hindered by a lack 
of control groups. A summary of the main studies examining 
the impact of islet transplantation on nephropathy is shown 
in Table 6.
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3.4 | Macrovascular complications
The DCCT showed that intensive glycaemic control im-
proves long- term cardiovascular outcomes6; therefore, 
we might expect that the improved glycaemic markers 
associated with ICT would be beneficial in slowing ath-
erosclerosis progression. However, immunosuppressive 
drugs have been implicated in increasing cardiovascular 
risk, particularly through adverse effects on blood pressure 
and lipids.12,23 In addition, cardiovascular disease follow-
ing whole organ transplantation remains one of the leading 
causes of morbidity and mortality.12 No prospective stud-
ies have assessed cardiovascular morbidity and mortality 
in nonuraemic, nonkidney transplanted islet transplant 
recipients.
Islet transplant recipients receiving a kidney graft have 
been studied. In one study, cardiovascular death rates were 
lower in IAK recipients with islet graft function (5%) versus 
T1D uraemic controls without a transplant (16%) and people 
who had received KTA (19%) and comparable with cardio-
vascular death rates in SPK recipients (8%). However, when 
islet transplanted participants with successful (n = 24) and 
unsuccessful (n  =  13) islet graft function were considered 
together, cardiovascular death rates were not reduced (18%) 
(S18).
Surrogate markers of cardiovascular disease and athero-
sclerosis have also been studied. A prospective follow- up 
study of carotid intima media thickness (CIMT) in 15 people 
receiving ICT demonstrated that the CIMT was significantly 
reduced at 12 months compared with pre- transplant baselines 
(S19). In parallel, there were improvements in glycaemic 
markers but no significant changes in blood pressure or lipids 
at follow- up versus pre- transplant. While most participants 
did have some progression of CIMT thickness after the initial 
large reduction in the first 12 months, the CIMT thickness 
remained significantly lower at 50 months follow- up (n = 7) 
for combined common and internal CIMT when compared 
with baseline values. Post- transplant C- peptide levels were 
not reported, but mean HbA1c at 50 months was 42 mmol/
mol (6%); there were no severe hypoglycaemic episodes 
reported during follow- up, and all 15 participants achieved 
insulin independence during the study. Of these, 11 partic-
ipants remained insulin free at last follow- up, and a further 
three had >50% reduction in insulin requirements. Graft loss 
was reported at 19 months in one participant. Further studies 
of CIMT in 17 people receiving IAK showed stable CIMT 
over 3 years compared with worsening CIMT in 25 people 
receiving KTA. Ejection fraction and peak filling rate in end- 
diastolic volume on echocardiogram were also improved in 
IAK versus KTA recipients (S20). The clinical significance 
of these markers remains uncertain. CIMT is a relatively 
well- established marker in clinical studies, but its use as a 
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less clear for individuals with other known cardiovascular 
risk factors (S21).
Other studies have demonstrated that ICT reduces pro-
thrombotic markers. Platelet size and aggregation, resting 
Ca2+ and levels of protein S and protein C were almost 
normalised to levels of healthy controls in 12 partici-
pants at 15  months post- islet transplant, in contrast to a 
control T1D group where markers were consistent with a 
prothrombotic state (increased platelet size and aggrega-
tion, increased resting Ca2+, reduced protein S and protein 
C).46 The authors postulate that the improved haemostatic 
indices in people with T1D post- transplant may reduce 
atherosclerosis risk by minimising a prothrombotic state. 
Individuals who had received kidney transplants on similar 
immunosuppression did not show any change to haemo-
static markers, suggesting the effects were not influenced 
by immunosuppression.
Clearly further evidence is needed to establish the risks 
and benefits for macrovascular outcomes following ICT 
and prospective studies in this field are urgently required. 
We summarise the current evidence for the effects of islet 
transplantation on macrovascular diabetes complications in 
Table 7.
4 |  FUTURE INNOVATIONS IN 
ISLET TRANSPLANTATION
Islet transplant alone presents ongoing challenges that limit 
the widespread use for people with T1D. SIK transplanta-
tion deserves particular mention as people with T1D with 
labile glycaemic control who require a kidney transplant 
benefit from this combined procedure with no additional 
immunological risks associated with receiving islets from 
the same donor (S22). Most pancreases cannot be used for 
islet transplantation because of prolonged ischaemic times, 
and patients usually require islets from at least two donors 
to impact on their insulin requirements, and in the United 
Kingdom, they may wait over 12 months to receive their 
first transplant. Furthermore, attrition in graft function is 
seen, due to nonimmunologic mechanisms of metabolic ex-
haustion of a marginal islet β- cell mass,19 and autoimmune 
and alloimmune mechanisms may contribute. The United 
Kingdom has expanded its donor criteria and uses islets 
from donors after cardiac death as well as after brain death. 
Many investigators are now researching how best to pre-
serve pancreases including with oxygen persufflation (S23) 
so as to use pancreases with marginally longer ischaemic 
times.
The cotransplantation of immunomodulatory cells includ-
ing mesenchymal stromal cells (MSCs) (S24) and T regula-
tory cells holds promise (S25). Such therapies may mean that 
people with T1D would only require islets from one donor 
pancreas therefore enabling the use of more donor organs to 
treat more people.
The need for long- term immunosuppression is a major 
concern. The use of encapsulated islets is in very early Phase 
1 studies, and if this approach is successful, it could poten-
tially make immunosuppression obsolete and justify this 
treatment for many more people with T1D (S26). However, 
fibrotic reactions around the device site are a major problem, 
and deviceless alternatives may hold more promise (S27) but 
still may not be immunosuppression free.
Islets derived from human embryonic stem cells and xe-
notransplantation, whereby transplantation of islets from 
a non- human animal source into a human recipient, offer a 
potentially unlimited supply of islets and is an area of active 
research (S28).
Finally, technological advances with hybrid closed- loop 
AID systems which automate basal insulin delivery but are 
not advanced enough to cover mealtime insulin requirements 
are now available but require significant user input; antici-
pated trials comparing ITA versus sensor augmented pump 
therapy are awaited.
Follow- on studies will be important to ascertain the im-
pact these therapies have on both overall glycaemic control 
particularly hypoglycaemia and awareness of hypoglycae-
mia, glycaemic stability, QoL measures and the impact on 
microvascular and macrovascular disease in the longer term.
5 |  CONCLUSION
Islet transplantation alone is indicated in people with 
T1D with SH and IAH where insulin therapy has been 
intensified and where there are no contraindications to 
immunosuppression. Metabolic outcomes show im-
proved glycaemic control, reduced hypoglycaemia with 
improved awareness of hypoglycaemia, diminished gly-
caemic variability with less dependence on insulin and 
improved QoL. Evidence suggests that islet transplanta-
tion confers benefits on microvascular endpoints includ-
ing retinopathy and neuropathy. Effects on renal function 
indicate a nephrotoxic impact of immunosuppressive 
medication in the short term, but in the longer term, renal 
function appears to stabilise. For those with coexisting 
renal transplants, nephropathy outcomes and macrovas-
cular benefits have been shown to be comparable with 
those receiving SPK. Long- term macrovascular outcomes 
are an area where prospective studies are needed, but sur-
rogate markers of cardiovascular disease are available 
and show improvements post- islet transplantation. In the 
future, as both adjuvant cell therapies as well as insu-
lin pump and sensor technologies advance, there will be 
opportunities to consider these alternatives in suitable 
individuals.
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